EUCTR2005-000350-69-DE进行中（未招募）不适用
A two-year extension to a one-year, multicenter, open-label, randomized study to evaluate the safety and efficacy of FTY720 combined with tacrolimus and steroids versus MMF (Cellcept) combined with tacrolimus and steroids, in de novo adult renal transplant recipients.
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 140
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •a)The patient has given written informed consent to participate in the extension study.
- •b)The patient has completed the Month 12 visit of the core study either on or off study medication.
- •c)Females capable of becoming pregnant are required to practice a medically approved method of birth control as long as they are on study medication and for a period of 3 months following discontinuation of study drug(s).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Not applicable.
研究者
相似试验
进行中（未招募）
不适用
A two-year extension to a one-year, multicenter, partially blinded, double-dummy, randomized study to evaluate the efficacy and safety of FTY720 combined with reduced-dose or full-dose Neoral and corticosteroids versus mycophenolate mofetil (MMF, CellCept) combined with full-dose Neoral and corticosteroids, in de novo adult renal transplant recipientsProphylaxis of kidney allograft rejection in de novo adult renal transplant recipientsMedDRA version: 7.0Level: LLTClassification code 10023439EUCTR2004-004377-28-SEovartis Pharma AG690
进行中（未招募）
不适用
A two-year extension to a one-year, multicenter, partially blinded, double-dummy, randomized study to evaluate the efficacy and safety of FTY720 combined with reduced-dose or full-dose Neoral and corticosteroids versus mycophenolate mofetil (MMF, CellCept) combined with full-dose Neoral and corticosteroids, in de novo adult renal transplant recipientsProphylaxis of kidney allograft rejection in de novo adult renal transplant recipientsMedDRA version: 7.0Level: LLTClassification code 10023439EUCTR2004-004958-63-DEovartis Pharma Services AG718
进行中（未招募）
不适用
A two years extension to a one year multicenter, partially blinded double dummy randomized study to evaluate the efficacy and safety of FTY720 combined with reduced dose or full dose Neoral and corticosteroids vs mycophenolate mofetil combined with full dose Neoral and corticosteroids in de novo adult renal transplant recipientsPrevention of the acute rejection in renal transplant patientMedDRA version: 6.1Level: PTClassification code 10023439EUCTR2004-004958-63-ITOVARTIS FARMA600
进行中（未招募）
1 期
A 2 year extension to a 36-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aliskiren on the prevention of left ventricular remodeling in high risk post-acute myocardial infarction patients when added to optimized standard therapyEssential HypertensionEUCTR2008-001306-16-BEovartis Pharma Services AG800
进行中（未招募）
不适用
A 2 year extension to a 36-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aliskiren on the prevention of left ventricular remodeling in high risk post-acute myocardial infarction patients when added to optimized standard therapyEssential HypertensionMedDRA version: 9.1Level: LLTClassification code 10015488Term: Essential hypertensionEUCTR2008-001306-16-HUovartis Pharma Services AG800